PATENT CLAIM ANALYSIS

Application Number: 15893771
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "415000"]

Abstract:
This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.

Claim (Index 1):
A crystalline form of: that is characterized by an X-ray powder diffraction (XRPD) pattern that has the representative peaks: Position [\u00b0 2Theta] d-spacing [\u212b] \u20029.2 \u00b1 0.1 9.6 11.4 \u00b1 0.1 7.8 11.9 \u00b1 0.1 7.4 13.8 \u00b1 0.1 6.4 15.4 \u00b1 0.1 5.7 17.8 \u00b1 0.1 5.0 18.0 \u00b1 0.1 4.9 18.5 \u00b1 0.1 4.8 18.7 \u00b1 0.1 4.7 23.2 \u00b1 0.1 3.8 when prepared by crystallization from a solvent that is other than a mixture of dichloromethane and hexanes.

Metadata:
- Claim Count in Document: 34.0
- Percentile: 88.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15111068', '13389525', '13941911', '15358458', '14549034']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7535532322872273
- 35 USC 102 Novelty (BERT): 0.5652512614058024
- Combined Prediction Score: 0.7347230351990848
- Mean Citation Score: 238.344134
- Max Citation Score: 441.6624
- Similarity Product: 363.89017237472535

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test